GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
The future of the weight loss market might not revolve around GLP-1 drugs.
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
3 No-Brainer Growth Stocks to Buy in October
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
MarketBeat on MSN20h
Why Eli Lilly Stock Is Soaring-and How It Plans to Stay on Top
In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company ...
thedailyupside9h
Weight-Loss Drugs Might Not Tank Medicare After All
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
Morningstar18h
Obesity Drug Market: The Next Wave of GLP-1 Competition
New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...